Back
Haemonetics 10K Form
Sell
50
HAE
Haemonetics
Last Price:
$62.97
Seasonality Move:
0.16%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-02-08 | 10Q | HAE/Haemonetics Quarterly |
2023-11-02 | 10Q | HAE/Haemonetics Quarterly |
2023-08-08 | 10Q | HAE/Haemonetics Quarterly |
2023-02-07 | 10Q | HAE/Haemonetics Quarterly |
2022-11-08 | 10Q | HAE/Haemonetics Quarterly |
2022-08-10 | 10Q | HAE/Haemonetics Quarterly |
Receive HAE News And Ratings
See the #1 stock for the next 7 days that we like better than HAE
HAE Financial Statistics
Sales & Book Value
Annual Sales: | $1.3B |
---|---|
Cash Flow: | $35.2M |
Price / Cash Flow: | 45.61 |
Annual Sales: | $18.05 |
Price / Book: | 3.49 |
Profitability
EPS (TTM): | 2.54000 |
---|---|
Net Income (TTM): | $130.1M |
Gross Margin: | $691.5M |
Return on Equity: | 14.16% |
Return on Assets: | 5.42% |
Haemonetics Earnings Forecast
Key Haemonetics Financial Ratios
-
The Gross Profit Margin over the past 33 years for HAE is 52.83%.
-
The Selling, General & Administrative Expenses for HAE have been equal to 32.98% of Gross Profit Margin.
-
The Research & Development expenses have been 4.16% of Revenue.
-
The Interest Expense is 11.07% of Operating Income.
-
The Net Earning history of HAE is 8.98% of Total Revenues.
-
Per Share Earnings over the last 34 years have been positive in 21 years.
Haemonetics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | HAE |
CUSIP: | 405024 |
Website: | haemonetics.com |
Debt
Debt-to-Equity Ratio: | 1.35 |
---|---|
Current Ratio: | 3.97 |
Quick Ratio: | 2.1 |
Price-to-Earnings
Trailing P/E Ratio: | 27.52 |
---|---|
Forward P/E Ratio: | 12.63 |
HAE Technical Analysis vs Fundamental Analysis
Sell
50
Haemonetics (HAE)
is a Sell
Is Haemonetics a Buy or a Sell?
-
Haemonetics stock is rated a SellThe current Haemonetics [HAE] share price is $63.02. The Score for HAE is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.